Tagged with BI

Canada Marc Wayne, serial entrepreneur and a pioneer within the field of medical cannabis discusses his dedication to the field, how cannabis-based therapies have the potential to disrupt the pharmaceutical industry and how now is a SMART time to conduct medical cannabis research.   The cannabis industry is a good example…

Canada Warren Bravo, co-founder and CEO of Green Relief, speaks about the company’s unique growing technique – aquaponics – which allows it to produce ‘better than organic’ medical cannabis. He gives an insight into the organization’s expansion plans, both within and beyond Canadian borders, and a potential IPO in 2018. After…

Canada Specializing on products adapted to the needs of seniors and long-term care patients, WeedMD is scaling up its production capacity to better meet the needs of this particular patient group while also preparing for the up-coming legalization of cannabis for recreational use. Bruce Dawson-Scully, WeedMD’s CEO and founder, shares his…

Baltics Roland Lepik, cluster head Baltics at Sandoz, discusses the company’s strategy that has allowed it to rank number one in the Estonian market along with the importance of ever-closer collaboration with key stakeholders to enhance the uptake of biosimilars. Roland, prior to joining Sandoz as Cluster Head Baltics you were…

India Murtaza Khorakiwala, managing director of Wockhardt, discusses the company’s vast international expertise in the manufacturing of pharmaceuticals and biopharmaceutical formulations in their 12 US FDA, UK MHRA and EMA compliant manufacturing facilities in India, as well as the out-licensing of its products into other regions to capture and penetrate new…

India As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus recently received permission to conduct Phase II clinical studies of Lipaglyn, the first drug to treat patients with nonalcoholic steatohepatitis…

Canada Moving into the position of National Pharma & Life Sciences Leader, PwC’s Rami El-Cheikh announces the firm’s plan to introduce the comprehensive Pharma Advisory Services currently existing in the US into Canada, including enterprise and function-specific service expertise. He further identifies areas of potential growth in healthcare-related industries, putting forward…

Poland Artur Chabowski, president of Mabion, a pioneer Polish biotech player, discusses the historic partnership of their product, MabionCD20 with Mylan for the EU and Baltic states and the opportunities this opens up. Furthermore, he highlights the future potential of the biosimilar market and the company´s plans to design their own…

Poland Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights Polpharma’s digital approach and the company’s long-term vision for sustained success across the region.   Our international markets are growing…

Lithuania Lithuania’s biotech sector has grown by between 20 and 25 percent over the last five years and accounts for over one percent of the entire country’s GDP. Key industry stakeholders are, however, split on whether Lithuania truly holds the potential to become a biotech hub that can stand alongside nations…

Canada At the company’s 40th anniversary, Biogen’s Canadian head Marina Vasiliou gives an insight into her priorities as new managing director, her approach to building relationships with all stakeholders in the healthcare system to ensure access to Biogen’s innovative treatments, and explains how the portfolio of the neuroscience leader is perfectly…

India Deloitte predicts that the global market for biosimilars will reach between USD 25 and 35 billion by 2020, driven by some key global biologic drugs facing loss of exclusivity in the next few years and an increasing global focus on improving healthcare access and the cost of care. Against this…